Roivant immune drug significantly outperformed placebo in treating rare skin disease

Roivant and its spinout Priovant have announced groundbreaking results from a recent trial of their immune-modifying drug brepocitinib. The drug showed significant efficacy in clearing lesions caused by a rare skin disease known as cutaneous sarcoidosis.

In the study, which included 31 participants, patients who received a high dose of brepocitinib experienced a remarkable average improvement of 22.3 points on a 165-point scale measuring disease activity. In contrast, patients who received a placebo only saw a marginal improvement of 0.7 points. These results far exceeded the expectations of company executives, who had initially set a benchmark of a five-point difference between the drug and placebo.

Misha Rosenbach, the lead investigator on the study and director of the cutaneous sarcoidosis program at the University of Pennsylvania Hospital, expressed enthusiasm about the findings. He stated, “The topline message I would want to convey is: You could not see better results in the drug. If the drug worked half as well and had twice as many side effects, this would still be a landmark study.”

The success of brepocitinib in this trial marks a significant milestone in the treatment of cutaneous sarcoidosis. The drug’s impressive performance has generated excitement within the medical community and raised hopes for improved therapeutic options for patients suffering from this rare skin condition.

For more in-depth coverage and analysis of the biotech sector, including exclusive articles like this one, readers can subscribe to STAT+. By subscribing, readers gain access to a wealth of valuable information and insights that can help them stay informed about the latest advancements in healthcare and biotechnology.